Window of opportunity

Estrogen as a treatment for ischemic stroke

Research output: Contribution to journalReview articleResearchpeer-review

25 Citations (Scopus)

Abstract

The neuroprotection research in the last 2 decades has witnessed a growing interest in the functions of estrogens as neuroprotectants against neurodegenerative diseases including stroke. The neuroprotective action of estrogens has been well demonstrated in both in vitro and in vivo models of ischemic stroke. However, the major conducted clinical trials so far have raised concern for the protective effect of estrogen replacement therapy in postmenopausal women. The discrepancy could be partly due to the mistranslation between the experimental stroke research and clinical trials. While predominant experimental studies tested the protective action of estrogens on ischemic stroke using acute treatment paradigm, the clinical trials have mainly focused on the effect of estrogen replacement therapy on the primary and secondary stroke prevention which has not been adequately addressed in the experimental stroke study. Although the major conducted clinical trials have indicated that estrogen replacement therapy has an adverse effect and raise concern for long term estrogen replacement therapy for stroke prevention, these are not appropriate for assessing the potential effects of acute estrogen treatment on stroke protection. The well established action of estrogen in the neurovascular unit and its potential interaction with recombinant tissue Plasminogen Activator (rtPA) makes it a candidate for the combined therapy with rtPA for the acute treatment of ischemic stroke. On the other hand, the critical period and newly emerged biomarkers window hypotheses have indicated that many clinical relevant factors have been underestimated in the experimental ischemic stroke research. The development and application of ischemic stroke models that replicate the clinical condition is essential for further evaluation of acute estrogen treatment on ischemic stroke which might provide critical information for future clinical trials. This article is part of a Special Issue entitled Hormone Therapy.

Original languageEnglish
Pages (from-to)83-90
Number of pages8
JournalBrain Research
Volume1514
DOIs
StatePublished - 13 Jun 2013

Fingerprint

Estrogens
Stroke
Estrogen Replacement Therapy
Clinical Trials
Therapeutics
Tissue Plasminogen Activator
Research
Neuroprotective Agents
Secondary Prevention
Neurodegenerative Diseases
Biomarkers
Hormones

Keywords

  • Estrogen
  • Ischemia
  • Neuroprotection
  • Neurovascular unit
  • Recombinant tissue plasminogen activator
  • Stroke

Cite this

@article{716fe2e6632746f8a5e0d74f03fedbee,
title = "Window of opportunity: Estrogen as a treatment for ischemic stroke",
abstract = "The neuroprotection research in the last 2 decades has witnessed a growing interest in the functions of estrogens as neuroprotectants against neurodegenerative diseases including stroke. The neuroprotective action of estrogens has been well demonstrated in both in vitro and in vivo models of ischemic stroke. However, the major conducted clinical trials so far have raised concern for the protective effect of estrogen replacement therapy in postmenopausal women. The discrepancy could be partly due to the mistranslation between the experimental stroke research and clinical trials. While predominant experimental studies tested the protective action of estrogens on ischemic stroke using acute treatment paradigm, the clinical trials have mainly focused on the effect of estrogen replacement therapy on the primary and secondary stroke prevention which has not been adequately addressed in the experimental stroke study. Although the major conducted clinical trials have indicated that estrogen replacement therapy has an adverse effect and raise concern for long term estrogen replacement therapy for stroke prevention, these are not appropriate for assessing the potential effects of acute estrogen treatment on stroke protection. The well established action of estrogen in the neurovascular unit and its potential interaction with recombinant tissue Plasminogen Activator (rtPA) makes it a candidate for the combined therapy with rtPA for the acute treatment of ischemic stroke. On the other hand, the critical period and newly emerged biomarkers window hypotheses have indicated that many clinical relevant factors have been underestimated in the experimental ischemic stroke research. The development and application of ischemic stroke models that replicate the clinical condition is essential for further evaluation of acute estrogen treatment on ischemic stroke which might provide critical information for future clinical trials. This article is part of a Special Issue entitled Hormone Therapy.",
keywords = "Estrogen, Ischemia, Neuroprotection, Neurovascular unit, Recombinant tissue plasminogen activator, Stroke",
author = "Ran Liu and Shaohua Yang",
year = "2013",
month = "6",
day = "13",
doi = "10.1016/j.brainres.2013.01.023",
language = "English",
volume = "1514",
pages = "83--90",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

Window of opportunity : Estrogen as a treatment for ischemic stroke. / Liu, Ran; Yang, Shaohua.

In: Brain Research, Vol. 1514, 13.06.2013, p. 83-90.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Window of opportunity

T2 - Estrogen as a treatment for ischemic stroke

AU - Liu, Ran

AU - Yang, Shaohua

PY - 2013/6/13

Y1 - 2013/6/13

N2 - The neuroprotection research in the last 2 decades has witnessed a growing interest in the functions of estrogens as neuroprotectants against neurodegenerative diseases including stroke. The neuroprotective action of estrogens has been well demonstrated in both in vitro and in vivo models of ischemic stroke. However, the major conducted clinical trials so far have raised concern for the protective effect of estrogen replacement therapy in postmenopausal women. The discrepancy could be partly due to the mistranslation between the experimental stroke research and clinical trials. While predominant experimental studies tested the protective action of estrogens on ischemic stroke using acute treatment paradigm, the clinical trials have mainly focused on the effect of estrogen replacement therapy on the primary and secondary stroke prevention which has not been adequately addressed in the experimental stroke study. Although the major conducted clinical trials have indicated that estrogen replacement therapy has an adverse effect and raise concern for long term estrogen replacement therapy for stroke prevention, these are not appropriate for assessing the potential effects of acute estrogen treatment on stroke protection. The well established action of estrogen in the neurovascular unit and its potential interaction with recombinant tissue Plasminogen Activator (rtPA) makes it a candidate for the combined therapy with rtPA for the acute treatment of ischemic stroke. On the other hand, the critical period and newly emerged biomarkers window hypotheses have indicated that many clinical relevant factors have been underestimated in the experimental ischemic stroke research. The development and application of ischemic stroke models that replicate the clinical condition is essential for further evaluation of acute estrogen treatment on ischemic stroke which might provide critical information for future clinical trials. This article is part of a Special Issue entitled Hormone Therapy.

AB - The neuroprotection research in the last 2 decades has witnessed a growing interest in the functions of estrogens as neuroprotectants against neurodegenerative diseases including stroke. The neuroprotective action of estrogens has been well demonstrated in both in vitro and in vivo models of ischemic stroke. However, the major conducted clinical trials so far have raised concern for the protective effect of estrogen replacement therapy in postmenopausal women. The discrepancy could be partly due to the mistranslation between the experimental stroke research and clinical trials. While predominant experimental studies tested the protective action of estrogens on ischemic stroke using acute treatment paradigm, the clinical trials have mainly focused on the effect of estrogen replacement therapy on the primary and secondary stroke prevention which has not been adequately addressed in the experimental stroke study. Although the major conducted clinical trials have indicated that estrogen replacement therapy has an adverse effect and raise concern for long term estrogen replacement therapy for stroke prevention, these are not appropriate for assessing the potential effects of acute estrogen treatment on stroke protection. The well established action of estrogen in the neurovascular unit and its potential interaction with recombinant tissue Plasminogen Activator (rtPA) makes it a candidate for the combined therapy with rtPA for the acute treatment of ischemic stroke. On the other hand, the critical period and newly emerged biomarkers window hypotheses have indicated that many clinical relevant factors have been underestimated in the experimental ischemic stroke research. The development and application of ischemic stroke models that replicate the clinical condition is essential for further evaluation of acute estrogen treatment on ischemic stroke which might provide critical information for future clinical trials. This article is part of a Special Issue entitled Hormone Therapy.

KW - Estrogen

KW - Ischemia

KW - Neuroprotection

KW - Neurovascular unit

KW - Recombinant tissue plasminogen activator

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84878513685&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2013.01.023

DO - 10.1016/j.brainres.2013.01.023

M3 - Review article

VL - 1514

SP - 83

EP - 90

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -